Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

In this week’s edition of InnovationRx, we look at a ‘holy grail’ pill for sleep apnea, Pomelo Care’s expansion, Nvidia and ...

Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...

After an agency review, the FDA asked drugmakers to remove warnings about a potential risk of suicidal thoughts from widely ...

A Covid vaccine researcher claims she was silenced for years right before warning the public about the dangers to certain ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is ...

FAYETTEVILLE, NY, UNITED STATES, January 9, 2026 /EINPresswire.com/ — January is traditionally a peak period for pharmaceutical list price adjustments. The AnalySource team analyzed Wholesale ...

HHS cancels mental health grants totaling $2 billion, ending hundreds of community-based addiction and mental health programs nationwide.

BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient ...

The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.